Replies to post #512969 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

That is correct— the survival for recurrent GBM was the most stellar of all the data. Dr. Stupp developed the SOC and he admits that nothing works for recurrent. Watch the Dr. Stupp video and hear his own words. Dr. Stupp asserts that rGBM is a “major unmet need” (minute 13:35). He highlights that no SOC treatment works for recurrent and that survival is always the same with current therapies (14:36).

https://www.youtube.com/embed/aHBkOhkKsrk (in case the first link does not work)

https://virtualtrials.org/dcvax.cfm

[SkyLimit2022]

Thank you for highlighting the most astonishing discovery of the DCVax P3—doubling rGBM survival. In fact, it was this discovery that prompted the Keytruda DCVax combo trial funded by NIH and Merck. GBM always becomes rGBM of course, so this discovery is of immeasurable significance.

RECURRENT GBM:

mOS: 13.2 mos vs. 7.8 mos from recurrence

Survival Tail: 20.7% vs. 9.6% at 24 mos after recurrence 11.1% vs. 5.1% at 30 mos after recurrence

https://virtualtrials.org/dcvax/dcvax.pdf

[Idunno]

Hygro, do you think, given your experience, that a financial entity, i.e. a ‘hedge fund’, is in fact short NWBO. And/or naked short? Could one fund have ‘inherited’ such a position from another? And, well, here we are? What’s your thoughts on these possibilities? I think, yes, possible. Many here think, maybe a long time ago, but not still. Given your experience, what do you think? Thanks.

[biosectinvestor]

No, they submitted it before they unblinded HyGro, saying otherwise, over and over again, does not change the facts. The SAP was submitted pre-data lock. And the reality is, for the same reason they understood that they had lost most of their placebo patients because they had almost all crossed over, they also knew that 1) they needed an external control arm, which they applied for and got from all the regulators pursuant to reforms at all of the regulators on the subject; and 2) they knew that while the placebo arm could not be used to show new Glioblastoma data because they had crossed over and the measure now was survival, those patients could now be used to show survival FROM recurrence and cross-over. Pretty elementary.